N IMPORTANT AREA of research on cellular differentiation is the identification of transcription factors regulating cell lineage-and differentiation stage-specific gene expression. Examples of such factors in the hematopoietic system are the Oct-2' and GATA family proteins.' Another transcription factor specific for hematopoietic cells is PU. 1, originally described as a lymphoid-and macrophagespecific f a~t o r .~.~ However, by gene targeting, PU.l was recently shown to be required for the development of multiple hematopoietic lineages.' PU. 1 belongs to the ets proto-oncogene family (including Etsl, Ets2, Erg, Elfl, GABPa, PEA3, Hi-l, E74A, Elkl, and SAP1) characterized by the wellconserved ETS domain that mediates specific DNA binding to the core sequence GGA. 6, 7 The N-terminal part of the protein, which is only weakly or not at all homologous to other Ets-proteins, contains a glutamine-rich transactivation domain8 and is able to bind to the TATA-box-binding protein and the retinoblastoma protein Rb in vitro.' PU.1 also contains a motif that mediates protein-protein interactions with the B-cell-specific transcription factor NF-EMS." PU.1 is identical to the oncogene Spi-l implicated in the development of spleen focus-forming virus-induced murine Friend erythroleukemia. Spleen focus-forming virus was found to integrate in the Spi-l locus in 95% of the tumors, resulting in an elevated expression of Spi-l mRNA." The observations that overexpression of Spi-1PU. 1 immortalizes primary erythroblasts12 and that antisense oligonucleotides inhibit the proliferation of Friend murine erythroleukemia cell linesI3 further indicated a role for Spi-1PU.1 in the growth control of immature erythroid cells. Also, the Etsfamily members v-Ets and Hi-l have been implicated in the development of erythroid tumors in chickens and mice, respe~tively.','~ The expression of PU. l in mature hematopoietic cells was reported to be confined to B cells, monocytes/macrophages, and mast cells, whereas it seems to be more broadly expressed at early stages of lymphoid and myeloid developdata which suggested that it is required for the early develop- ment of several lineages.' The PU.l binding site, the socalled Pu box, has been identified as an important tissuespecific regulatory element in the promoters or enhancers of a number of differentiation-associated genes in different hematopoietic cell Thus, PU.l has been implicated as an important tissue-specific factor regulating these genes in intimate cooperation with other transcription factors (such as NF-EMS," or Sp12') or other Ets-family members (such as Etsl," Erg-3," or GABPaZ3).
We are interested in the role of PU. 1 during development of human B-lineage cells and its possible involvement in tumor formation in these cells. A panel of human B-cell lines representing different stages of development, from early precursors to differentiated plasma cells, was used for studies of PU.1 expression and activity. We found differences in PU.l mRNA expression, PU.l DNA binding, and transcriptional activity in cell lines at different maturation stages. In particular, we can show that PU.l activity and expression was shut off in a panel of multiple myeloma cell lines, representing differentiated B cells. The implications of these findings will be discussed.
Nuclear extracts were prepared from 40 X IO" cells using the lysolecithin procedure described by Zervitz and Akusjarvi." Ten micrograms of extract was used for each binding reaction, and 1 pg poly(d1-dC)poly(dl-dC) (Pharmacia) and 10 pmol single-stranded oligonucleotide were included as nonspecific competitors. EMSA with the Pu box was performed in a buffer containing 10 mmol/L HEPES (pH 7. formaldehyde (4 mUl00 mL gel). After electrophoresis, the RNA was transferred to a nitrocellulose filter. The probes were "P-labeled by the random priming method (Amersham, Buckinghamshire, UK). Hybridization was performed at 42°C in a solution containing 50% formamide, I X Denhardt's solution, 2X SSC (2X SSC: 0.3 mol/L sodium chloride and 30 mmol/L sodium citrate), S mmol/L NaPO.,, 0.1% sodium dodecyl sulfate, and 200 pg/mL of salmon sperm DNA. Filters were washed in O S % sodium dodecyl sulfate and 2X SSC at 50°C and exposed to Kodak XAR film (Eastman Kodak, Rochester, NY). A murine PU.1 cDNA clone (unpublished, Dr L. Hellman, Department of Medical Immunology and Microbiology, University of Uppsala, Sweden) and a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA clon$' were used as probes. (Fig 2, lanes 2-8) . In contrast, three of the myeloma cell lines, U-1996, U-266-1970, and U-266-1 984, were completely negative; in the other two, L363 and Karpas 707, a very faint band could be detected (Fig 2, lanes 11-15) . Compared with early and mature B-cell lines, a reduced PU.1 binding activity was observed in the lymphoblastoid cell lines, in particular in Corinna I1 (Fig 2, lanes 9 and IO) . Figure 3 shows that an oligonucleotide containing an Spl binding site showed specific Spl binding activity in the myeloma cell extracts as well as in BJA-B extracts, thus ruling out a general degradation of the myeloma extracts.
RESULTS

Absence
Absence of Pu box-dependent transcriptional activio in multiple myeloma cell lines. We next investigated whether the observed binding of PU.1 to the Pu box in the various extracts correlated with transcriptional activity. Four copies of the Pu box oligonucleotide and a mutated version thereof were cloned upstream of the SV40 early promoter in a CAT gene construct. The plasmids were transfected into selected B-cell lines, and, 72 hours after transfection, the cells were harvested and assayed for CAT activity. A construct with the SV40 early promoter and enhancer sequences was 1 2 3 4 5 6 7 8 A control CAT reporter plasmid containing SV40 promoter and enhancer sequences strongly stimulated transcription in the myeloma cell lines. We were also unable to detect any Pu box-dependent transcriptional activity in the Corinna I1 lymphoblastoid cell line, which has a reduced PU. 1 binding activity. The PU.1 gene is downregulated in multiple myeloma cell lines. The lack of PU. 1 activity in the myeloma cells could be because of a downregulation of the PU. I gene expression or, alternatively, because the protein is present in an inactive form. To investigate the expression of PU. 1 in the panel of B-cell lines used above, RNA was prepared, and a Northern blot analysis was performed using a mouse PU.1 cDNA as probe. Figure 5A shows that the 1.4-kb PU. I transcript was expressed in all B-cell lines with the exception of the myeloma cell lines, in which it was undetectable even after prolonged exposure. The lymphoblastoid cell line U-255 showed a reduced expression, and the level of PU. I mRNA was very low, but detectable, in Corinna 11. As a control, the same filter was rehybridized with a GAPDH probe, showing that this gene was expressed in all cell lines (Fig 5B) . We conclude that the PU.1 gene is shut off in the myeloma IN HUMAN B CELLS   2751 precursor cells. It has also been suggested to play a role in mature B cells and macrophages. We have undertaken a study to investigate the presence and activity of PU. 1 during human B-cell development using a panel of human B-cell lines representing the B-cell lineage from early precursors to differentiated plasma cells.
Our This interpretation would be in agreement with previous expression studies suggesting that PU.1 is expressed in early myeloidflymphoid cells committed to the erythroid, granulocytic, monocytic, mast cell, B-and T-lymphoid lineages. It is then shut off early in T-cell, erythroid, and granulocytic differentiation but is expressed at later stages of monocytic, mast cell, and B-cell differentiati~n.~~~"'"~ The present data may suggest that it is shut off late during B-cell differentiation, thus performing its function at preterminal stages of B-cell development. From this perspective, the differences in expression in human myelomas and murine plasmacytomas may be because of slight differences in maturation stage or a malignancy-associated inability to shut off PU. 1 in the plasmacytomas or might represent a species difference. Studies of PU.l expression in normal human and mouse plasma cells are required to clarify these points. It may seem remarkable that PU.l is shut off in human myeloma cell lines that produce Ig at a high level, because PU. 1 has been suggested to be one important transcriptional activator of both the heavy-and light-chain Ig However, there are alternative pathways of Ig gene regulation mediated by, for instance, Oct-2 and NF-KB, acting on the heavy chain enhancer and on the K-chain intron enhancer, respectively, that seem to increase in importance at late stages of B-cell differentiati~n.'~,~',~~ Therefore, such alternative pathways may be in operation in the human myeloma cell lines. Other genes suggested to be regulated by PU.l in B cells are the J-chain,' the mb-l and B29 antigen receptorassociated signaling proteins,'8320 p2 i n t e g r i n~,~~ and the major histocompatibility complex class I1 antigens4 The expression of these genes seems to be connected to B-cell activation, proliferation, and IgM secretion at preterminal stages of differentiation rather than to terminally differentiated plasma cells or myelomas.
Therefore, one interesting possibility is that PU.l might be a transcription factor which integrates differentiation and cell growth at proliferative stages along the B-cell differentiation lineage. The oncogenic potential of PU.l/Spi-l in erythroleukemia and its ability to interact with Rb in vitro would point in this direction. Immunohistochemical studies in normal murine bone barrow also suggest the highest expression of PU.l in dividing cells." An attractive hypothesis is that PU.l is replaced by an alternative Ets-family or a non-Ets transcription factor such as Oct-2 or NF-KB, lacking proliferative or having an antiproliferative capacity, at terminal stages of B-cell differentiation in which high expression of the differentiation-associated genes is connected to irreversible growth-arrest. Examples of other Ets-family members expressed in hematopoietic cells are Etsl, Ets2, Erg, Fli-l, Elfl, GABPa, and/or S P~B .~ The EMSA and transactivation assays in the myelomas suggest that PU.l is not replaced by an Ets-family protein with capacity to bind the SV40 Pu box. However, other PU. 1 binding sites in relevant cellular target genes may have a broader Ets-family binding specificity that could result in a competition between different Ets-family proteins or a sequential role of these during B-cell development. Further studies of PU.1 and other Etsfamily proteins during normal B-cell development is re- 
